Dianthus Therapeutics
DNTH · NASDAQ
$78.75+$4.21 (+5.65%)TodayMarket closed ·
Prev close $74.54
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 8.8% on average
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- -$0.96
- Revenue estimate
- $433.14K
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.8748 | -$0.90 | −2.9% |
| Q1 FY26 | -$1.09 | -$0.85 | +22.3% |
| Q4 FY25 | -$1.10 | -$1.43 | −30.3% |
| Q3 FY25 | -$0.8796 | -$0.97 | −10.3% |
| Q2 FY25 | -$0.8891 | -$0.88 | +1.0% |
| Q1 FY25 | -$0.866 | -$0.82 | +5.3% |
| Q4 FY24 | -$0.8679 | -$0.81 | +6.7% |
| Q3 FY24 | -$0.6063 | -$0.74 | −22.1% |
Earnings calls
- Citigroup’s Biopharma Back to School Summit 2026
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Special Call - Dianthus Therapeutics, Inc.
- Guggenheim Securities Emerging Outlook: Biotech Summit 2026
- 44th Annual J.P. Morgan Healthcare Conference
- Special Call - Dianthus Therapeutics, Inc.
- 43rd Annual J.P. Morgan Healthcare Conference 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.